Primatene MIST was approved earlier this month for over-the-counter (OTC) use for the temporary relief of mild symptoms of intermittent asthma (eg, wheezing, tightness of chest, shortness of breath) in patients aged ≥12 years.
In the asthma clinical trials, the most common adverse reactions were injection site reactions, oropharyngeal pain, and eosinophilia.
PubMed was searched to obtain data on the relative efficacies of benralizumab, dupilumab, lebrikizumab, mepolizumab, reslizumab, and tralokinumab.
Results from the extension trial showed a similar safety and tolerability profile for Fasenra as that seen in SIROCCO and CALIMA.
According to the report, the patient complained of a non-productive cough, accumulation of mucus, and post-nasal drip and requested a thorough assessment of her medical conditions.
Currently, 3 anti-interleukin (IL)5 pathway-directed treatments (benralizumab, mepolizumab, reslizumab) have been approved by the Food and Drug Administration for the treatment of severe asthma with an eosinophilic phenotype
The designation was based on data from the Phase 2b PATHWAY trial that evaluated 3 doses of tezepelumab as add-on therapy in patients with a history of asthma exacerbations and uncontrolled asthma receiving inhaled corticosteroids/long-acting β-agonist with or without oral corticosteroids and additional asthma controllers vs placebo.
The authors write that once severe asthma is diagnosed, clinicians should determine asthma endotype (Type2-high or Type2-low) to help choose the best therapy for the patient.
The Hailie sensor attaches to the asthma or chronic obstructive pulmonary disease (COPD) inhaler to monitor and help patient adherence.
Iatrogenic steroid-induced psychosis is a rare side effect of glucocorticoid therapy which is mostly seen in adults, although it has been reported in children and adolescents.
The Smartinhaler sensor is a device installed onto a patient's inhaler to monitor and promote asthma and COPD medication adherence.
Dupixent is a human monoclonal antibody specifically designed to inhibit signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13), two important signaling proteins (cytokines) that contribute to Type 2 inflammation in moderate-to-severe asthma.
Severe asthma is a challenging condition. Available therapeutic options for severe asthma include tiotropium, omalizumab, interleukin-5 targeted therapies, macrolide antibiotics, and bronchial thermoplasty.
Qvar RediHaler (beclomethasone dipropionate HFA) Inhalation Aerosol is a breath-actuated inhaled prescription medicine used as a maintenance treatment for the prevention and control of asthma in people 4 years of age and older.
To examine real-world clinician adherence to these guidelines, as well as agreement and self-efficacy, researchers analyzed data from the 2012 National Asthma Survey of Physicians.
The food, beverage and tobacco manufacturing industry (1.82) had the highest elevated asthma PMRs for men. Among women, the social assistance industry (1.35) and community social services occupations (1.46) had the highest elevated asthma PMRs.
Fasenra is indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.
Consistent reductions in asthma attacks and improvements in lung function across a broad population of uncontrolled asthma patients.
Results found that overall depression was the most commonly reported adverse event in the VigiBase group while headaches were the most frequent adverse event reported for the Dutch database.
Among the re-treated patients, almost 90% achieved symptom control (UAS7 ≤6) within 3 months. During both dosing periods, Xolair 150mg and 300mg were well-tolerated
Results found that at 52 weeks severe asthma attacks were reduced by 46% in the overall population for the 300mg dose group and by 60% and 67% among those patients with ≥150 eosinophilic cells/microliter or greater and ≥300 eosinophilic cells/microliter, respectively (P<0.001).
The SmartTouch for Symbicort is a monitoring device that is installed onto the patient's inhaler to track and improve medication adherence.